Comparative Effectiveness of Antidiabetic Drugs As an Additional Therapy to Metformin in Women with Polycystic Ovary Syndrome: A Systematic Review of Metabolic Approaches

Overview

Journal Int J Endocrinol

Publisher Wiley

Specialty Endocrinology

Date 2024 Mar 19

PMID 38500709

Authors

Maryam Heidarpour

Mehrzad Mojarad

Sadegh Mazaheri-Tehrani

Ali Kachuei

Arash Najimi

Davood Shafie

Hassan Rezvanian

Affiliations

Soon will be listed here.

Abstract

Background: Metformin is commonly prescribed to treat polycystic ovary syndrome (PCOS) patients, but in some cases, it may not be effective even at high doses or may cause intolerable side effects. Therefore, recent studies have examined the impact of combining metformin with other antidiabetic medications.

Methods: A systematic search was performed in Scopus, PubMed, Web of Science, and Embase up to 30 June 2023. All interventional studies that assessed the efficacy of different antidiabetic agents were included.

Results: Among the 3488 records found in the primary search, 16 papers were included. Our study showed that dipeptidyl peptidase-4 inhibitors (DPP4i) had the most significant impact on glycemic profile, while thiazolidinediones (TZDs) had the most influence on lipid levels. However, it was observed that patients taking only metformin experienced a greater increase in high-density lipoprotein cholesterol (HDL-C) levels. Glucagon-like peptide-1 receptor agonists (GLP1RAs) effectively modified various anthropometric measurements, such as weight, body mass index, waist circumference, and waist-to-hip ratio. The effects of different antidiabetic drugs on hormone levels were inconclusive, although testosterone levels were more affected by GLP1RA, sodium-glucose cotransporter-2 inhibitors (SGLT2i), and TZDs. None of the combined therapies showed a significant change in blood pressure.

Conclusion: Since PCOS is a metabolic disorder, choosing the best combination of antidiabetic drugs in the clinical course of PCOS patients will be very important. Today, it seems that we need a new metabolic approach for better treatment of the metabolic aspects of these patients.

Citing Articles

Is it feasible to treat polycystic ovarian syndrome with or without insulin resistance using glucokinase activators as novel hypoglycaemic medications? A protocol for a systematic review and meta-analysis.

Zeng G, Lu X, Li P, Zeng T, Lin Z, Miao Y BMJ Open. 2025; 14(12):e088484.

PMID: 39806679 PMC: 11667369. DOI: 10.1136/bmjopen-2024-088484.

Serum Selenium Levels and Lipid Profile: A Systematic Review and Meta-analysis of Observational Studies.

Mazaheri-Tehrani S, Abhari A, Ostadsharif N, Shekarian A, Vali M, Saffari E Biol Trace Elem Res. 2024; .

PMID: 39256333 DOI: 10.1007/s12011-024-04365-4.

References

Li Y, Tan J, Wang Q, Duan C, Hu Y, Huang W . Comparing the individual effects of metformin and rosiglitazone and their combination in obese women with polycystic ovary syndrome: a randomized controlled trial. Fertil Steril. 2019; 113(1):197-204. DOI: 10.1016/j.fertnstert.2019.09.011. View

McCreight L, Bailey C, Pearson E . Metformin and the gastrointestinal tract. Diabetologia. 2016; 59(3):426-35. PMC: 4742508. DOI: 10.1007/s00125-015-3844-9. View

Cahn A, Cernea S, Raz I . An update on DPP-4 inhibitors in the management of type 2 diabetes. Expert Opin Emerg Drugs. 2016; 21(4):409-419. DOI: 10.1080/14728214.2016.1257608. View

Liao L, Tian Y, Zhao J, Xin Y, Xing H, Dong J . Metformin versus metformin plus rosiglitazone in women with polycystic ovary syndrome. Chin Med J (Engl). 2011; 124(5):714-8. View

Ko K, Kim K, Lee K . Does Weight Gain Associated with Thiazolidinedione Use Negatively Affect Cardiometabolic Health?. J Obes Metab Syndr. 2019; 26(2):102-106. PMC: 6484909. DOI: 10.7570/jomes.2017.26.2.102. View

Inoue H, Tamaki Y, Kashihara Y, Muraki S, Kakara M, Hirota T . Efficacy of DPP-4 inhibitors, GLP-1 analogues, and SGLT2 inhibitors as add-ons to metformin monotherapy in T2DM patients: a model-based meta-analysis. Br J Clin Pharmacol. 2018; 85(2):393-402. PMC: 6339993. DOI: 10.1111/bcp.13807. View

Joham A, Norman R, Stener-Victorin E, Legro R, Franks S, Moran L . Polycystic ovary syndrome. Lancet Diabetes Endocrinol. 2022; 10(9):668-680. DOI: 10.1016/S2213-8587(22)00163-2. View

Shahid R, Iahtisham-Ul-Haq , Mahnoor , Awan K, Iqbal M, Munir H . Diet and lifestyle modifications for effective management of polycystic ovarian syndrome (PCOS). J Food Biochem. 2022; 46(7):e14117. DOI: 10.1111/jfbc.14117. View

Yang S, Zhao L, He W, Mi Y . The Effect of Oral Antidiabetic Drugs on Improving the Endocrine and Metabolic States in Women with Polycystic Ovary Syndrome: A Systematic Review and Network Meta-analysis. Drugs. 2022; 82(14):1469-1480. DOI: 10.1007/s40265-022-01779-z. View

10.

Tang T, Glanville J, Hayden C, White D, Barth J, Balen A . Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum Reprod. 2005; 21(1):80-9. DOI: 10.1093/humrep/dei311. View

11.

Abdalla M, Shah N, Deshmukh H, Sahebkar A, Ostlundh L, Al-Rifai R . Impact of metformin on the clinical and metabolic parameters of women with polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials. Ther Adv Endocrinol Metab. 2022; 13:20420188221127142. PMC: 9548689. DOI: 10.1177/20420188221127142. View

12.

Jensterle Sever M, Kocjan T, Pfeifer M, Kravos N, Janez A . Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur J Endocrinol. 2013; 170(3):451-9. PMC: 3922503. DOI: 10.1530/EJE-13-0797. View

13.

Kim J, Ahn C, Fang S, Lee H, Park J . Association between metformin dose and vitamin B12 deficiency in patients with type 2 diabetes. Medicine (Baltimore). 2019; 98(46):e17918. PMC: 6867725. DOI: 10.1097/MD.0000000000017918. View

14.

Gilbert M, Pratley R . GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials. Front Endocrinol (Lausanne). 2020; 11:178. PMC: 7145895. DOI: 10.3389/fendo.2020.00178. View

15.

Sadeghi H, Adeli I, Calina D, Docea A, Mousavi T, Daniali M . Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing. Int J Mol Sci. 2022; 23(2). PMC: 8775814. DOI: 10.3390/ijms23020583. View

16.

Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R . Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008; 93(7):2670-8. DOI: 10.1210/jc.2008-0115. View

17.

Pasquali R, Renato P . Metformin in women with PCOS, pros. Endocrine. 2014; 48(2):422-6. DOI: 10.1007/s12020-014-0311-1. View

18.

Maruthur N, Tseng E, Hutfless S, Wilson L, Suarez-Cuervo C, Berger Z . Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. Ann Intern Med. 2016; 164(11):740-51. DOI: 10.7326/M15-2650. View

19.

Daneshjou D, Mehranjani M, Zadehmodarres S, Shariatzadeh S, Mofarahe Z . Sitagliptin/metformin improves the fertilization rate and embryo quality in polycystic ovary syndrome patients through increasing the expression of GDF9 and BMP15: A new alternative to metformin (a randomized trial). J Reprod Immunol. 2022; 150:103499. DOI: 10.1016/j.jri.2022.103499. View

20.

Zhang J, Xing C, Cheng X, He B . Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial. Front Endocrinol (Lausanne). 2022; 13:1003238. PMC: 9486461. DOI: 10.3389/fendo.2022.1003238. View